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Apolar trisubstituted derivatives of harmine show high antiproliferative activity on diverse cancer cell
lines. However, these molecules present a poor solubility making these compounds poorly bioavailable.
Here, new compounds were synthesized in order to improve solubility while retaining antiproliferative
activity. First, polar substituents have shown a higher solubility but a loss of antiproliferative activity.
Second, a Comparative Molecular Field Analysis (CoMFA) model was developed, guiding the design and
synthesis of eight new compounds. Characterization has underlined the in vitro antiproliferative char-
acter of these compounds on ﬁve cancerous cell lines, combining with a high solubility at physiological
pH, making these molecules druggable. Moreover, targeting glioma treatment, human intestinal ab-
sorption and blood brain penetration have been calculated, showing high absorption and penetration
properties.
© 2015 The Authors. Published by Elsevier Masson SAS. This is an open access article under the CC BY-NC-
ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Harmine (1) is a natural b-carboline compound, which is amajor
alkaloid from Peganum harmala and Banisteriopsis caapi, presenting
antiproliferative activity. This later property is attributed to several
mechanisms of action such as antiangiogenesis activity on endo-
thelial cells [1,2], apoptosis induction [3] or reverse drug resistance
by inhibition of the Breast Cancer Resistance Protein-mediated
drug efﬂux protein [4]. Based on these antiproliferative proper-
ties, our group previously synthesized about ﬁfty harmine de-
rivatives 2aeas substituted on the 2, 7 or/and 9 position(s)
(structure on Supporting information) [5]. Their in vitro growth
inhibitory activity (determination of the IC50 concentration) was
evaluated on three glioma (U373, T98G, Hs683) and two oeso-
phageal cancer cell lines (OE21, OE33) from human origin. This
work highlighted that the 2,7,9-trisubstituted compounds were theeinguet).
Masson SAS. This is an open accessmost potent derivatives with some of them reaching a sub-
micromolar antiproliferative activity (Fig. 1) [5]. Moreover, the
growth inhibitory potency of the best compounds was in the same
range, both on cells resistant or not to apoptotic stimuli [6].
Quantitative videomicroscopy have shown a cytostatic behaviour
on U373 glioma cell line [5].
To elucidate the mechanism of action of the 2aec anti-
proliferative molecules, anti-cancer proﬁles on the 60 cancer cell
line panel of the National Cancer Institute (Bethesda, USA) were
evaluated and compared to those of the 763,000 compounds of the
NCI database [7]. The highest correlation was found with protein
synthesis inhibitors, an hypothesis that was further conﬁrmed by
western blot on the eukaryotic initiation factor 2 (eiF2a) implicated
in protein synthesis [5,8].
Despite a strong antiproliferative activity in vitro, these trisub-
stituted compounds possess a poor solubility at physiological pH,
which is detrimental for their bioavailability and their development
as drug [9]. In order to obtain novel druggable harmine-based
antiproliferative molecules, and following the concept of early-
ADME which leads to improve both biological and ADMEarticle under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-
Fig. 1. Structure and measured solubility (pH7.4, rt) for compounds 1, 2aec.
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b-carboline derivatives preserving their antiproliferative activity on
cancer cells [10]. On one hand, new b-carbolines were synthesized
bearing polar substituents in order to a priori improve their solu-
bility. On the other hand, a Comparative Molecular Field Analysis
(CoMFA) model was generated to guide the synthesis of new
molecules. The physicochemical properties (solubility, lip-
ophilicity) and the antiproliferative activity (MTT colorimetric test,
quantitative videomicroscopy) have been investigated for each
newly synthesized compound. Finally, tomimic oral absorption and
brain uptake which is required for glioma treatment, human in-
testinal absorption and blood brain barrier penetration have been
calculated.2. Results
2.1. Chemistry
Targeted 2,7,9-trisubstituted compounds (4feh and 5cej) and
intermediates (Table 1) discussed in this work were synthesized
following the strategy depicted on Scheme 1 [5]. Starting from
harmol, the 7-desmethyl harmine, two routes have been adopted
to obtain 7,9-disubstituted derivatives. First pathway, used when
R7 is different from R9, is a two-step procedure involving O7-
alkylation of harmol by an alkyl-, a branched alkyl- or benzyl
bromide in presence of caesium carbonate in DMF (2j, 3) (a). Then,
the O7-substituted compound reacts with iodopropane and sodium
hydride under argon in DMF to give the 7,9-disubstituted com-
pounds 2w and 5a (b). A different strategy was used to obtain 4a. In
this case, 3 reacts with acrylonitrile and Triton B to add the N9-
propionitrile substituent (c) [11]. In the second pathway, used
when R7 is identical to R9, 4b and 5b were synthesized by a
simultaneous O7- and N9- alkylation of harmol using the required
alkylbromide and potassium hydroxide in DMF (d). 2,7,9-
trisubstituted compounds 5cej were obtained by a N2-alkylation
of the corresponding 7,9-disubstituted compound in presence of
the required alkylbromide in THF (e). The nitrile derivative 4e,
obtained by the pathway (e), was converted into the corresponding
tetrazole (4f) by using sodium azide and ammonium chloride in
DMF (f) [11]. Hydroxyl alkyl substituents, benzyl ethers 4c and 4d,obtained following (e) pathway, were reduced by Pd-catalysed
hydrogenation using Pd/C affording 4g and 4h respectively (g)
[12]. These last two reactions led to targeted trisubstituted com-
pounds bearing charged (4f) or neutral (4geh) polar substituent(s)
unlike targeted compounds 5cej which only bear apolar sub-
stituents. The structure and purity of each ﬁnal synthesized com-
pound were analysed by 1H NMR, 13C NMR, LC, MS and elemental
microanalyses.
2.2. Physicochemical characterization
Experimental aqueous solubility at pH 7.4 and theoretical lip-
ophilicity (Advanced Chemistry Development, Inc., ACD/Lab) [13] of
compounds 4feh and 5cej were compared with the results ob-
tained for the most active b-carboline of the ﬁrst generation (2aec)
as shown in Table 1. Aryl and cycloalkyl substituents of 2aec are
responsible for their high molecular weight (MW > 500 g/mol) and
lipophilicity (logP>5) over Lipinski's rules [14]. Moreover, the poor
solubility of 2aec is due to the presence of an aryl, an aryl halide or
a cyclohexyl substituent. Addition of hydroxylated substituents
(4geh) or small branched/linear alkyl moieties (5cej) strongly
improves the solubility at physiological pH which become higher
than 200 mg/ml and 160 mg/ml, respectively. Each newly synthe-
sized compound (4feh and 5cej) offers, as expected, a lower mo-
lecular weight (MW < 500 g/mol) and a decreased lipophilicity
(logP<5).
2.3. Biological characterization
a) Determination of the in vitro growth inhibitory activity
Determination of in vitro growth inhibitory activity was per-
formed on three glioma cell lines (U373, T98G, Hs683), one mela-
noma (SKMEL-28) and one lung cancer (A549) cell line using a MTT
colorimetric assay [15]. Cells were cultured during three days in
presence (test) or absence (control) of 4feh and 5cej compound at
concentrations from 10 nM to 100 mM. For each b-carboline, the
concentration required to reduce the global growth by 50% (the IC50
concentration) was determined on each cell line (Table 2). Com-
pounds 4feh bearing polar substituents (tetrazole or hydroxyalkyl)
Table 1
Chemical structure, calculated lipophilicity (clogP), measured solubility (pH 7.4) of compounds 2aec, 3, 4aeh and 5aej.
Cmpd Chemical structure Calculated LogP Measured solubility,
pH 7.4, at rt (mg/ml)
R7 R9 R2
2a CH2eC6H5 CH2eC6H5 CH2eC6H5 5.27 ± 1.51 72.5 ± 3.8
2b 30-ﬂuorobenzyl 30-ﬂuorobenzyl 40-ﬂuorobenzyl 5.39 ± 1.53 2.4 ± 0.6
2c CH2-cyclohexyl CH2-cyclohexyl CH2eC6H5 6.73 ± 1.51 <1.7
3 (CH2)2eCH(CH3)2 e e NDa ND
4a (CH2)2eCH(CH3)2 (CH2)2eCN e ND ND
4b (CH2)2eO-Bn (CH2)2eO-Bn e ND ND
4c (CH2)2eO-Bn (CH2)2eO-Bn (CH2)2eCH(CH3)2 ND ND
4d (CH2)2eO-Bn (CH2)2eO-Bn (CH2)2eO-Bn ND ND
4e (CH2)2eCH(CH3)2 (CH2)2eCN (CH2)2eCH(CH3)2 ND ND
4f (CH2)2eCH(CH3)2 (CH2)2-tetrazole (CH2)2eCH(CH3)2 1.86 ± 1.54 ND
4g (CH2)2eOH (CH2)2eOH (CH2)2eCH(CH3)2 1.11 ± 1.51 >218.7
4h (CH2)2eOH (CH2)2eOH (CH2)2eOH 2.6 ± 1.52 >205.6
5a (CH2)2eCH(CH3)2 CH2CH2CH3 e ND ND
5b CH2CH2CH3 CH2CH2CH3 e ND ND
5c CH2CH2CH3 CH2CH2CH3 CH2CH3 2.09 ± 1.51 173.8 ± 5.5
5d CH2CH2CH3 CH2CH2CH3 (CH2)2eCH(CH3)2 2.46 ± 1.51 195.9 ± 5.2
5e CH2eC6H5 CH2CH2CH3 CH2CH3 2.36 ± 1.51 207.4 ± 3.5
5f CH2eC6H5 CH2CH2CH3 (CH2)2eCH(CH3)2 2.74 ± 1.51 163.7 ± 6.2
5g CH2eC6H5 CH2CH2CH3 CH2eCH(CH3)2 2.43 ± 1.51 207.1 ± 4.2
5h (CH2)2eCH(CH3)2 CH2CH2CH3 CH2CH3 2.95 ± 1.51 186.2 ± 4.6
5i (CH2)2eCH(CH3)2 CH2CH2CH3 CH2CH2CH3 3.06 ± 1.51 185.1 ± 2.2
5j (CH2)2eCH(CH3)2 CH2CH2CH3 CH2eCH(CH3)2 3.32 ± 1.51 189.2 ± 13.4
a ND: Not determined.
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charge at physiological pH (4f) or not (4geh). On the contrary,
molecules 5cej exhibit an IC50 concentration in the micromolar to
submicromolar range which makes these compounds more active
than harmine (IC50 ¼ 28 mM) [5]. It is interesting to highlight that:
- For the same substituent on the N2- and N9-positions, the IC50 is
20-times lower when the O7-propyl is replaced by an isopentyl
moiety (5c vs 5h and 5d vs 5j).
- Within the O7-isopentyl derivative series, activity is improved
when R2 is also a branched alkyl (5he5j).
These observations underline the important effect of branched
substituents of the harmine skeleton on antiproliferative effect.
b) Cytotoxic and cytostatic effects of compounds on U373, Hs683
and SKMEL-28 cells
As 2aec display cytostatic activity on U373 glioma cell line at
IC50 concentration [5], we examined the antiproliferative activity of
the best inhibitors (5f, 5h, 5j) on the same U373 glioma cell line as
well as on Hs683 glioma and SKMEL-28 melanoma cell lines using
quantitative videomicroscopy (Fig. 2) (results on Hs683 and
SKMEL-28 in Supporting information). Cells were seeded and
cultured 72 h in the presence (test) or absence (control) of the b-
carboline derivative, at a concentration corresponding to their IC50
concentration determined by theMTTcolorimetric test. A picture of
the bottom ﬂask is registered each 4 min during the 72 h of
observation. The condensation of the 1080 images generated a 40s
movie for each experiment operated in triplicate. Results on the
three tested cell lines show a morphological cytostatic effect of the
compounds 5f, 5h and 5j at their IC50 concentration, which are 1, 1
and 0.5 mM respectively.2.4. Computational chemistry
In order to generate a CoMFA model, 49 structures of b-carbo-
lines (1, 2a-as and 4feg compounds) were aligned on a pharma-
cophore to have alignment principally based on substituents. This
alignment was performed in two steps in order to produce the best
alignment of b-carboline compounds. The ﬁrst step aimed to
generate a starting pharmacophore with 2a, 2ae and 2ap (see
structures in Supporting information) as training set with merged
features. Based on this ﬁrst pharmacophore, information about the
harmine tricycle and the positive charge were removed in order to
generate a bias pharmacophore including only information about
the substituents. In the second step, a second pharmacophore was
generated based on the bias pharmacophore with 2ac, 2aq, 2ae and
2c as training set. The ﬁnal alignment of all compounds, performed
with LigandScout 3.03 [16], is depicted on Fig. 3A. The CoMFA
model was generated on Sybyl 8.1 software [17] on 80% of the
molecules (training set). Thesemolecules were chosen randomly by
Discovery Studio 3.5 [18]. The remaining 20% molecules were used
as a test set. CoMFA model was elaborated using pIC50 activity on
Hs683 cell line.
PLS statistics obtained during the development of the model are
summarized in Table 3. The cross-validated correlation coefﬁcient
(q2) represents the prediction capacity of the model and the con-
ventional correlation coefﬁcient (r2) represents the capacity to ﬁt
the data with the 3D-QSAR model. The high value of r2 indicates a
good ﬁtting of the derived model [19]. Moreover, the low standard
error of estimate (0.314) and the important value for Fisher test
indicate that an important part of the data is explained by the
model. Contributions of steric and electrostatic ﬁelds are similar
with 46.1% and 53.9%, respectively. The experimental versus pre-
dicted pIC50 data are depicted on Fig. 4, showing a good prediction
of data for training and test sets (data are summarized in
Supporting information for 1, 2aeas and in Table 2 for 4feh).
Scheme 1. Synthesis of b-carbolines derivatives 2j, 2w, 3, 4aeh, 5aej. (a) R7Br (1.5 equiv), Cs2CO3 (3 equiv), DMF, rt; (b) iodopropane (1.5equiv), NaH (5 equiv), DMF, Ar, rt, 24 h; (c)
acrylonitrile (7 equiv), Triton B, rt; (d) R7(¼R9)Br (2 equiv), KOH (5 equiv), DMF, Ar, rt, 24 h; (e) R2Br (10 equiv), THF, D, microwave, 140 C, 3 h; (f) NaN3 (4.5 equiv), NH4Cl (4 equiv),
DMF, rt; (g) H2, Pd/C 10%, EtOH, rt.
Table 2
In Vitro IC50 growth inhibitory potency after 3 days culture in presence of compounds 4feh or 5cej on various cancer cell lines, compared to predicted IC50 on Hs683 by CoMFA
model.
Cmpd IC50 (mM) Predicted IC50
on Hs683 (mM)
Residualsb
Mean þ SEM Lung cell line Melanoma cell line Glioma cell lines
A549 SKMEL-28 U373 T98G Hs683
4f >100 >100 >100 NDa ND >100 43.6c >56.4
4g >100 >100 >100 >100 ND >100 50.8c >49.2
4h >92 51 ± 6 51 ± 6 >100 ND >100 103.0c <3
5c 13 ± 6 0.7 8 35 22 2 18.6d 16.6
5d 6 ± 4 2 3 22 4 1 3.4d 2.4
5e 8 ± 4 2 4 22 11 3 7.5d 4.5
5f 1.0 ± 0.3 0.3 1 2 1.5 0.3 1.0d 0.7
5g 1.3 ± 0.6 0.8 0.6 1.0 3.8 0.4 1.8d 1.4
5h 0.6 ± 0.2 0.2 1.0 0.6 0.9 0.09 11.1d 11.0
5i 0.6 ± 0.2 0.3 0.9 0.6 1.2 0.04 1.9d 1.7
5j <0.3 0.1 0.4 0.2 0.7 <0.01 1.6d >1.6
a ND: Not Determined.
b Residuals deﬁne as difference between experimental IC50 and predicted IC50 on Hs683 cell line.
c Included in CoMFA model training set.
d Predicted based on CoMFA model results.
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penetration calculation
Calculations have been performed with Discovery Studio soft-
ware, using two developed models based on descriptors such as 2D
polar surface area and AlogP98 calculations [18,20]. Models deﬁne
four prediction levels for the intestinal absorption (from good to
very poor) and blood brain barrier (from very high to low pene-
trants plus an undeﬁned level) after oral administration. These
different levels are deﬁned by conﬁdence ellipsoids at 95% and 99%.
For human intestinal absorption, compounds depicted inside the
ellipsoids are determined as well absorbed compounds (>90%
absorbed) while compounds outside ellipsoids are predicted as
poorly absorbed compounds (<30% absorbed). For blood brain
barrier penetration, the deﬁnition is quite different: molecules
outside the ellipsoids are undeﬁned, while in the ellipsoids four
regions are drawn corresponding to the four levels of BBB pene-
tration. Fig. 5 shows that 2aec compounds are predicted as verypoorly absorbed by human intestines (A) and are undeﬁned with
respect to their blood brain penetration (B), while compounds 5cej
are characterized by a good intestinal absorption (A) and very high
brain penetration (B), therefore making these compounds more
druggable.3. Discussion and conclusions
In order to improve the solubility of 2,7,9-trisubstituted harmine
derivatives with antiproliferative activity and to expand the range
of studied substituents, compounds bearing polar substituents
(4feh) have been synthesized and their physicochemical proper-
ties (Table 1) and antiproliferative efﬁcacy (Table 2) were evaluated.
Results indicate that polar substituents on b-carboline template
increase solubility (>200 mg/ml) at physiological pH, as expected,
but unfortunately, strongly reduce their antiproliferative activity
with a mean IC50 higher than 100 mM. Moreover, compared to the
growth inhibitory activity of harmine (IC50 ¼ 28 mM) [5], the IC50
Fig. 2. Quantitative videomicroscopy analyses of the compounds 5f, 5 h and 5j on U373 glioma cell line. Compounds were tested at their IC50 value which was previously
determined by the MTT colorimetric test.
Fig. 3. (A) Alignment of compounds 1, 2a-as and 4feh established with LigandScout 3.03. (B) CoMFA contour maps on 2a. (B.1.) Steric ﬁeld: green contour indicates a favourable
group and yellow contour indicates an unfavourable group (B.2.) Electrostatic ﬁeld: Blue contour indicates positively charge and H-donor favourable, red contour indicates an
unfavourable positively charged and H-donor group. (For interpretation of the references to colour in this ﬁgure legend, the reader is referred to the web version of this article.)
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antiproliferative activity of trisubstituted b-carbolines.
As an alternative, a CoMFA model has been generated based on
1, 2a-as and 4feh biological activity in order to suggest molecules
combining antiproliferative activity in the micromolar range and
higher solubility than compounds 2aec. This model gives a good
prediction of pIC50 values compared to experimental pIC50 values
on Hs683 glioma cell line (Fig. 4) and highlights steric and elec-
trostatic contributions essential for antiproliferative activity. In
order to visualize CoMFA model, contour maps were generatedaround compound 2a (Fig. 3B). Several conclusions can be drawn
based on these maps; ﬁrstly, the nature of O7-substituent has little
inﬂuence on the biological activity; secondly, N9- and N2-sub-
stituents must be sterically small; thirdly, the positive charge due to
the presence of the third substituent is favourable to biological
activity.
Based on these observations and in order to decrease the lip-
ophilicity of initial molecules, diverse small substituents including
propyl, isopentyl and benzyl were linked to the harmine ring
(5cej). Combination of these substituents leads to 8 newmolecules
Table 3
PLS statistics of CoMFA model.
q2a Nb r2c SEEd Fe Fractionf
Steric Electrostatic
CoMFA 0.397 3 0.872 0.314 73.220 46.1 53.9
a Crossvalidated correlation coefﬁcient.
b Optimum number of components obtained by PLS analysis and used in the non-
validated analysis.
c Conventional correlation coefﬁcient.
d Standard error of estimate.
e Fisher-test value.
f Contributions ﬁeld.
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(Table 1). Moreover, their biological activity on Hs683 glioma cell
predicted by the CoMFAmodel suggest that those molecule present
an antiproliferative effect in themicromolar range (Table 2). Among
these 8 molecules, three of them, bearing an ethyl substituents on
R2 position (5c, 5e, 5h) (not included in the training set) are pre-
dicted as less active than the others compounds. However, as these
three molecules present a lower molecular weight and calculated
lipophilicity compared to initial compounds, these molecules have
been synthesized and included in our study.
Physicochemical characterization underlined a higher solubility
of these compounds 5cej compared to 2aec. Because the reference
molecules (2aec) and targeted molecules 5cej have the same b-
carboline skeleton, we can relate the best solubility and lip-
ophilicity to the decreased number of carbon atoms substituting
the molecules, which make these compounds more “druggable”
than 2aec. Biological characterization highlighted that these sol-
uble compounds offer an antiproliferative activity in the micro-
molar to submicromolar range on ﬁve cancerous cell lines. 5f, 5h
and 5j are the best antiproliferative compounds. Moreover, the
experimental antiproliferative activity of compounds bearing an
ethyl moiety (5c, 5e and 5h) present a submicromolar IC50 on
Hs683 glioma cells, despite a poor CoMFA prediction (Table 2). This
conclusion highlights the underestimated inhibitory potential of
the ethyl substituent (not part of training set) by the generated
model.
As the ﬁrst generation of harmine substituted compounds
(2aec) has a cytostatic proﬁle on U373 glioma cell line, quantitative
videomicroscopy experiment was performed on the new mole-
cules, highlighting a similar cytostatic behaviour of these com-
pounds on three cancerous cell lines including two glioma cell
lines.
With the aim to develop novel antiproliferative b-carboline
which are orally bioavailable and focussing particularly on glioma
treatment, human intestinal absorption and blood brain barrier
penetration of newly synthesized compounds were calculated withFig. 4. Predicted versus experimental pIC50 values for training set (C) and test set (▫).Discovery Studio 3.5 software [18]. Results show better intestinal
absorption and bloodebrain barrier penetration for 5cej com-
pounds compared to 2aec. Fig. 5 shows that the different features
of compounds 2aec and 5cej are due to their difference in lip-
ophilicity rather than their 2D polar surface area, which is the same
for these molecules characterized by the same skeleton bearing
apolar substituents. Compounds 2aec, with aromatic substituents,
are too lipophilic (logP>5) which is not propitious for a good oral
bioavailability, as opposed to 5cej compounds substituted by small
alkyl groups, which have a lower lipophilicity (logP<3.4) and are
predicted to be very well absorbed.
In conclusion, in the continuation of our previous results
showing that trisubstituted b-carbolines 2aec present an anti-
proliferative activity but a low solubility at pH 7.4 and using an
early-ADME concept, new molecules combining antiproliferative
activity and an improved solubility at pH 7.4 have been synthesized.
After synthesis of these new harmine derivatives bearing polar
substituents, a CoMFA model was generated with the b-carboline
derivatives aligned on substituents. The good statistical values
obtained for this CoMFA model (q2 ¼ 0.397, r2 ¼ 0.872) has guided
synthesis to sterically small substituents on R2 and R9 positions to
increase biological activity. Based on this model, we thus synthe-
sized eight new molecules (5cej) with a good predicted anti-
proliferative activity and a decreased lipophilicity compared to the
compounds of the ﬁrst generation 2aec. Synthesis, physicochem-
ical and biological characterization leads to high soluble originalFig. 5. (A) human intestinal absorption and (B) blood brain barrier penetration pre-
diction for compounds 2aec (-) and 5cej (C). Human intestinal absorption is deﬁned
by 99% (mauve line) and 95% (blue line) ellipsoids. Blood brain barrier penetration is
deﬁned by 99% (grey line) and 95% (yellow line) ellipsoids.
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5j compounds. Our results are in agreement with those recently
presented by Cao and co-workers who have also presented good
antiproliferative activity for trisubstituted harmine derivatives [21].
Quantitative videomicroscopy underlines a cytostatic effect of
these three molecules on U373, Hs683 and SKMEL-28 cancer cell
lines. Moreover, human intestinal absorption and blood brain bar-
rier penetration has been calculated for 5cej, compared with initial
compounds (2aec) and suggests better druggability of the newly
synthesized molecules mainly due to their decreased lipophilicity.
4. Experimental section
4.1. Chemistry
Melting points were measured on a Buchi Melting Point B540
apparatus in open capillaries with uncorrected values. All NMR (1H
and 13C) were recorded on Jeol spectrometer (JNM EX-400) at 25 C.
Chemical shifts are reported in parts per million (ppm) using the
solvent residual peak as reference (DMSO-d6: dH: 2.50 ppm, dC:
39.52 ppm; CD3OD: dH: 3.31 ppm, dC: 49.00 ppm). Coupling con-
stants (J) are reported in Hertz (Hz). The resonance multiplicity is
described as s for singlet, d for doublet, t for triplet, q for quadruplet
and m for multiplet. LC-MS analyses was realized on an Agilent
1100 series HPLC coupled with an MSD Trap SL system, using
detection at 254 nm equipped with an Agilent Zorbax Eclipse XDB
C8 4.6 mm 150 mm, 5 mm separation column in a 70:30 solution
of 0.01 M sodium 1-butanesulfonate in methanol/0.01 M sodium 1-
butanesulfonate in water as eluent. Mass determination was real-
ized using electron spray ionization (ESI) in positive mode. High
resolution mass spectrometry (HRMS) were obtained from ESI-Q-
TOF, maXis Impact (Bruker). Elemental analyses were determined
on a FlashEA 1112 series organic elemental analyzer. Thin-layer
chromatography was realized on silica gel plates (silica gel GF254,
VWR) visualized at 254 nm. Column chromatography was realized
in a BiotageSP1 25 þ M column equipped with UV spectropho-
tometer with a detector (wavelengths of 254 nm and 320 nm).
Solvents from Biosolve were used without further puriﬁcation.
Microwave irradiation was realized on a Biotage initiator 2.0
apparatus in 20 ml sealed tube. All new compounds were deter-
mined to be >95% pure by LC-MS.
General procedure for simultaneous O-7 and N-9 alkylation
(A): The synthesis was performed as described elsewhere [5].
Brieﬂy, harmol (1.50 g, 5 mmol) was dissolved in DMF (30 ml). An
amount of 5 equiv of potassium hydroxide was added and the
mixture was stirred for 30 min under argon. Then, 2 equiv of alkyl
bromide was added. The mixture was stirred at room temperature
overnight under argon. The reaction was followed by TLC (85:15
dichloromethane: ethanol). At the end of the reaction, the mixture
was extracted using dichloromethane. The organic layer was
washed with water and brine and dried with MgSO4, which was
collected by ﬁltration. The organic layer was evaporated under
vacuum and the crude product was puriﬁed via column chroma-
tography with dichloromethane/ethanol (100:0 to 70:30) used as
the eluent.
General procedure O-7 alkylation (B): The synthesis was per-
formed as described elsewhere [22]. Brieﬂy, harmol (1.5 g, 5 mmol)
was dissolved in DMF (30 ml). An amount of 1.5 equiv of alkyl
bromide and 3 equiv of caesium carbonate were added. The
mixture was stirred during 24 h at room temperature, under argon.
The reaction was followed by TLC (85:15 dichloromethane:
ethanol). At the end of the reaction, the mixture was extracted
using dichloromethane. The organic layer was washed with water
and brine and dried with MgSO4, which was collected by ﬁltration.
The organic layer was evaporated under vacuum and the crudeproduct was puriﬁed via column chromatography with dichloro-
methane/ethanol (100:0 to 80:20) used as the eluent.
General procedure for N-9 alkylation (C): The 1-methyl-O7-
substituted-7-hydroxy-b-carboline (1.25 g) was dissolved in DMF.
An amount of 1.5 equiv of iodopropane and 5 equiv of sodium hy-
dride were added. The mixture was stirred overnight under Argon.
The reaction was followed by TLC (85:15 dichloromethane:
ethanol). At the end of the reaction, the mixture was extracted
using dichloromethane. The organic layer was washed with water
and brine and dried with MgSO4, which was collected by ﬁltration.
The organic layer was evaporated under vacuum and the crude
product was puriﬁed via column chromatography with dichloro-
methane/ethanol (100:0 to 87:13) used as the eluent.
General procedure for microwave assisted synthesis of N-2
alkylation (D): The synthesis was performed as described else-
where [5]. Brieﬂy, 1-methyl-O7-substituted-N9-substituted-7-
hydroxy-b-carboline (0.300 g) was dissolved in THF (10 ml). An
amount of 10 equiv of alkyl bromide was added. The mixture was
placed on a microwave reactor at 140 C during 4 h. The reaction
was followed by TLC (85:15 dichloromethane: ethanol). At the end
of the reaction, precipitate was ﬁltrate without any puriﬁcation or
the mixture was extracted using dichloromethane. The organic
layer was washed with water and brine and dried with MgSO4,
which was collected by ﬁltration. The organic layer was evaporated
under vacuum and the crude product was puriﬁed via column
chromatography with dichloromethane: ethanol (100:0 to 70:30)
used as the eluent.
Synthesis. Synthesis of compounds 2ae2as has been previously
reported [5,22].
4.1.1. 7-(Isopentyloxy)-1-methyl-b-carboline, 3
The title compound was synthesized according to the general
procedure B from 1-methyl-7-hydroxy-b-carboline (harmol)
(1.98 g, 7.4 mmol) in the presence of caesium carbonate (7.21 g,
22.2 mmol), 1-bromo-3-methylbutane (1.4 ml, 11.1 mmol) in 50 ml
of DMF. A yellow solid was obtained. Yield 65%, Mp 235e237 C,
MS: [MþH]þ 269.0, Rf ¼ 0.4 (85:15 dichloromethane: ethanol), 1H
NMR (DMSO-d6) d: 0.92 (d, J ¼ 6.64 Hz, 6H, CH-(CH3)2), 1.64 (m, 2H,
CH2eCHe(CH3)2), 1.75e1.85 (m, 1H, CH-(CH3)2), 2.67 (s, 3H, CH3),
4.06 (t, J ¼ 6.64 Hz, 2H, OeCH2), 6.79 (dd, J68 ¼ 2.06 Hz,
J56 ¼ 8.59 Hz, 1H, H-6), 6.96 (d, J68 ¼ 2.06 Hz, 1H, H-8), 7.75 (d,
J34 ¼ 5.27 Hz, 1H, H-4), 7.99 (d, J56 ¼ 8.47 Hz, 1H, H-5), 8.10 (d,
J34 ¼ 5.27 Hz, 1H, H-3), 11.35 (bs, 1H, NH), 13C NMR (DMSO-d6) d:
20.86, 23.02, 25.18, 37.98, 66.64, 95.76, 109.94, 112.43, 115.39,
123.12,127.74,135.05,138.25,141.761,142.45,159.96, Anal. Calcd for
C17H20N2O: C, 76.09%; H, 7.51%; N, 10.44%. Found: C, 76.08%; H,
7.56%; N, 10.17%.
4.1.2. 7-(Isopentyloxy)-1-methyl-9-propionitrile-b-carboline, 4a
The title compound was synthesized according a method
describe elsewhere [11]. 3 (1.289 g, 4.5 mmol) and acrylonitrile
(3.0 ml, 45 mmol) were stirred. Addition dropwise of TritonB
(0.28 ml, 1.54 mmol) leads to a red solution followed by TLC (85:15
dichloromethane: ethanol). After completion of the reaction, the
mixture was extracted with dichloromethane (100 ml) and organic
layer was washed with water and brine. The organic layer was
evaporated under vacuum and the crude product was used without
any puriﬁcation. An orange solid was obtained. Yield quant, Mp:
166e167 C, MS: [MþH]þ 322.0, Rf ¼ 0.8 (85:15 dichloromethane:
ethanol), 1H NMR (Acetone-d6) d: 0.97 (d, J ¼ 6.64 Hz, 6H, CH-
(CH3)2), 1.68e1.74 (m, 2H, OeCH2eCH2), 1.82e1.92 (m, 1H, CH-
(CH3)2), 3.01 (s, 3H, CH3), 3.10 (t, J ¼ 6.87 Hz, 2H, NeCH2eCH2), 4.18
(t, J ¼ 6.64 Hz, 2H, OeCH2), 5.02 (t, J ¼ 6.87 Hz, 2H, NeCH2eCH2),
6.90 (dd, J56 ¼ 8.59 Hz, J68 ¼ 2.06 Hz, 1H, H-6), 7.33 (d,
J68 ¼ 2.06 Hz, 1H, H-8), 7.81 (d, J34 ¼ 5.04 Hz, 1H, H-4), 8.04 (d,
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(Acetone-d6) d: 18.07, 22.06, 23.05, 25.03, 38.01, 40.17, 66.64, 94.25,
110.36, 112.02, 115.13, 117.80, 122.24, 129.42, 134.92, 138.81, 140.84,
142.64, 160.78.
4.1.3. 7-(2-Benzyloxyethoxy)-9-(2-benzyloxyethyl)-1-methyl-b-
carboline, 4b
The title compound was synthesized according to the general
procedure A from harmol (1.98 g, 7.4 mmol) in the presence of
benzyl-2-bromoethylether (2.4 ml, 14.8 mmol) and potassium hy-
droxide (2.10 g, 37 mmol) in 40 ml of DMF. A white solid was ob-
tained after crystallization in EtOH. Yield 52%, Mp 82e83 C, MS:
[MþH]þ 467.0, Rf ¼ 0.9 (85:15 dichloromethane: ethanol), 1H NMR
(DMSO- d6) d: 2.92 (s, 3H, CH3), 3.75e3.81 (m, 4H,
NeCH2eCH2 þ OeCH2eCH2), 4.20 (t, J ¼ 5.04 Hz, 2H, OeCH2), 4.32
(s, 2H, CH2-Ar), 4.54 (s, 2H, CH2-Ar), 4.75 (t, J¼ 5.27 Hz, 2H, NeCH2),
6.86 (dd, J56 ¼ 8.59 Hz, J68 ¼ 2.06 Hz, 1H, H-6), 6.99e7.01 (m, 2H,
AreH), 7.12e7.37 (m, 9H, AreH, AreH, H-8), 7.86 (d, J34 ¼ 5.27 Hz,
1H, H-4), 8.05 (d, J56 ¼ 8.47 Hz, 1H, H-5), 8.14 (d, J34 ¼ 5.04 Hz,
1H, H-3), 13C NMR (DMSO- d6) d: 23.85, 44.76, 68.08, 68.77, 69.42,
72.60, 72.68, 95.38, 110.27, 112.81, 114.89, 122.86, 127.45, 127.78,
127.99, 128.07, 128.59, 128.79, 129.04, 135.65, 137.88, 138.61, 138.86,
141.32, 143.54, 160.16.
4.1.4. 7-(2-Benzyloxyethoxy)-9-(2-benzyloxyethyl)-2-isopentyl-1-
methyl-b-carbolin-2-ium bromide, 4c
The title compound was synthesized according to the general
procedure D from 4b (0.307 g, 0.6 mmol) in the presence of 1-
bromo-3-methylpropane (0.78 ml, 6.4 mmol) in 15 ml of THF. A
grey solid was obtained after crystallization in EtOH. Yield 33%, Mp
163e164 C, MS: [M]þ 537.1, Rf ¼ 0.4 (85:15 dichloromethane:
ethanol), 1H NMR (DMSO- d6) d: 0.93 (d, J¼ 6.41 Hz, 6H, CH-(CH3)2),
1.57e1.63 (m, 2H, NeCH2eCH2), 1.65e1.72 (m, 1H, CH-(CH3)2), 3.16
(s, 3H, CH3), 3.80e3.85 (m, 4H, NeCH2eCH2 þ OeCH2eCH2),
4.28e4.32 (m, 4H, OeCH2 þ CH2-Ar), 4.56 (s, 2H, CH2-Ar), 4.63 (t,
J¼ 6.18 Hz, 2H, NeCH2), 4.95 (t, J¼ 4.81 Hz, 2H, NeCH2), 6.88e6.90
(m, 2H, AreH), 7.07e7.14 (m, 4H, AreH), 7.25e7.33 (m, 5H, AreH),
7.43 (s, 1H, AreH), 8.93 (d, J ¼ 8.93 Hz, 1H, AreH), 8.52 (d, 1H,
J34 ¼ 6.41 Hz, 1H, H-4), 8.62 (d, 1H, J34 ¼ 6.41 Hz, 1H, H-3), 13C
NMR (DMSO- d6) d:16.74, 22.71, 26.04, 45.83, 56.29, 68.54, 69.06,
72.67, 72.71, 95.67, 113.34, 113.77, 114.87, 124.93, 127.47, 127.90,
128.04, 128.08,128.60,128.82,113.12,135.36,136.09,138.36,138.78,
139.99, 147.73, 162.94.
4.1.5. 7-(2-Benzyloxyethoxy)-2,9-bis(2-benzyloxyethyl)-1-methyl-
b-carbolin-2-ium bromide, 4d
The title compound was synthesized according to the general
procedure D from 4b (0.394 g, 0.84 mmol) in the presence of
benzyl-2-bromoethylether (2.0 ml, 12.7 mmol) in 15 ml of THF. A
green solid was obtained. Yield 54%, Mp 149e150 C, MS: [M]þ
601.0, Rf ¼ 0.3 (85:15 dichloromethane: ethanol), 1H NMR (DMSO-
d6) d: 3.18 (s, 3H, CH3), 3.81e3.87 (m, 6H,
OeCH2eCH2 þ NeCH2eCH2 þ NeCH2eCH2), 4.30e4.34 (m, 4H,
OeCH2þ CH2-Ar), 4.40 (s, 2H, CH2-Ar), 4.55 (s, 2H, CH2-Ar), 4.92 (m,
4H, NeCH2 þNeCH2), 6.91 (m, 2H, AreH), 7.10e7.17 (m, 9H, AreH),
7.25e7.33 (m, 5H, AreH), 7.41, (m, 1H, AreH), 8.32 (d, J ¼ 8.70 Hz,
1H, AreH), 8.49 (d, J34 ¼ 6.41 Hz, 1H, H-4), 8.55 (d, J34 ¼ 6.41 Hz,
1H, H-4), 13C NMR (DMSO- d6) d: 17.14, 45.87, 56.99, 68.53, 68.69,
69.02, 72.54, 72.64, 72.67, 95.66, 113.31, 113.81, 114.24, 124.95,
127.50, 127.80, 127.88, 128.03, 128.09, 128.60, 128.72, 128.81, 133.36,
135.77, 136.17, 138.20, 138.33, 138.79, 140.60, 147.94, 162.99.
4.1.6. 2-Isopentyl-7-(isopentyloxy)-1-methyl-9-propionitrile-b-
carbolin-2-ium bromide, 4e
The title compound was synthesized according to the generalprocedure D from 4a (0.282 g, 0.9 mmol) in the presence of 1-
bromo-3-methylpropane (1.7 ml, 14 mmol) in 15 ml of THF. A yel-
low solid was obtained after crystallization in EtOH. Yield 15%, Mp
199e201 C, MS: [M]þ 392.1, Rf ¼ 0.2 (85:15 dichloromethane:
ethanol), 1H NMR (DMSO- d6) d: 0.93e0.97 (m, 12H, CH-(CH3)2þ
CH-(CH3)2), 1.66e1.74 (m, 5H, CH2eCH-(CH3)2 þ CH2eCH-(CH3)2),
1.73e1.85 (m, 1H, CH2eCH-(CH3)2), 3.14 (t, J ¼ 6.41 Hz, 2H,
CH2eCN), 4.20 (t, J ¼ 6.64 Hz, 2H, OeCH2), 4.69 (t, J ¼ 7.10 Hz, 2H,
NeCH2), 5.07 (t, J ¼ 6.64 Hz, 2H, NeCH2), 7.08 (dd, J68 ¼ 1.83 Hz,
J56 ¼ 8.93 Hz, 1H, H-6), 7.55 (d, J68 ¼ 1.60 Hz, 1H, H-8), 8.32 (d,
J56 ¼ 8.93 Hz, 1H, H-5), 8.53 (d, J34 ¼ 6.41 Hz, 1H, H-4), 8.67 (d,
J34 ¼ 6.64 Hz, 1H, H-3), 13C NMR (DMSO- d6) d: 16.52, 18.69, 22.74,
22.98, 25.15, 26.02, 29.56, 37.84, 41.06, 56.30, 67.50, 95.41, 113.14,
114.19, 114.87, 119.12, 124.96, 133.62, 135.11, 135.97, 139.92, 147.39,
163.41.
4.1.7. 9-(2-[1H-tetrazol-5-yl]ethyl)-2-isopentyl-7-(isopentyloxy)-
1-methyl-b-carbolin-2-ium bromide, 4f
The title compound was synthesized according a procedure
describe elsewhere [11]. 4e (0.349 g, 0.74 mmol) in the presence of
sodium azide (0.217 g, 3.3 mmol) and ammonium chloride (0.155 g,
2.9 mmol) in 4 ml of DMF was reﬂuxed 12 h. The reaction was
followed by TLC (85:15 dichloromethane: ethanol). After comple-
tion of the reaction, the mixture was extracted with dichloro-
methane and organic layer was washed with water and brine and
dried withMgSO4. The organic layer was evaporated under vacuum
and the crude product was puriﬁed via column chromatography
with dichloromethane/ethanol (100:0 to 50:50) used as the eluent.
A white solid was obtained after crystallization in EtOH. Yield 19%,
HRMS Calcd for C25H35N6Oþ: 435.2867 [M]þ. Found: 435.2859,
Rf ¼ 0.4 (CH2Cl2/ethanol 50/50), 1H NMR (DMSO- d6) d: 0.95e0.97
(m, 12H, CH-(CH3)2þ CH-(CH3)2), 1.64e1.74 (m, 5H, CH2eCH-
(CH3)2 þ CH2eCH-(CH3)2), 1.75e1.87 (m, 1H, CH2eCH-(CH3)2), 3.08
(s, 3H, CH3) 3.19 (t, J¼ 6.87 Hz, 2H, CH2eCN), 4.17 (t, J¼ 6.41 Hz, 2H,
OeCH2), 4.60 (t, J ¼ 7.33 Hz, 2H, NeCH2), 4.96 (t, J ¼ 7.33 Hz, 2H,
NeCH2), 7.00 (dd, J68 ¼ 1.83 Hz, J56 ¼ 8.82 Hz, 1H, H-6), 7.25 (d,
J68 ¼ 1.83 Hz, 1H, H-8), 8.28 (d, J56 ¼ 8.70 Hz, 1H, H-5), 8.47 (d,
J34 ¼ 6.41 Hz, 1H, H-4), 8.57 (d, J34 ¼ 6.64 Hz, 1H, H-3).
4.1.8. 7-(2-Hydroxyethoxy)-9-(2-hydroxyethyl)-2-isopentyl-1-
methyl-b-carbolin-2-ium bromide, 4g
The title compound was synthesized from 4c (0.160 g,
0.26 mmol) in the presence of Pd/C 10% (41.6 mg, 0.04 mmol) and
H2 (1 bar) in 20 ml of ethanol. The reaction was followed by TLC
(85:15 dichloromethane: ethanol). After completion of the reaction,
the mixture was ﬁltered under celite and was evaporated under
vacuum. The crude extract was crystallized with hot ethanol to give
the title compound. A yellow solid was obtained after crystalliza-
tion in EtOH. Yield 96%, Mp 232e234 C, HRMS Calcd for
C21H29N2O3þ: 357.2173 [M]þ. Found: 357.2174, Rf ¼ 0.1 (85:15
dichloromethane: ethanol), 1H NMR (DMSO- d6) d: 0.96 (d,
J¼ 5.72 Hz, 6H, CH-(CH3)2),1.65e1.73 (m, 3H, CH2eCH-(CH3)2), 3.23
(s, 3H, CH3), 3.76e3.83 (m, 4H, CH2eOH þ CH2eOH), 4.19 (t,
J ¼ 4.81 Hz, 2H, OeCH2), 4.69 (t, J ¼ 7.33 Hz, 2H, NeCH2), 4.77 (t,
J ¼ 4.81 Hz, 2H, NeCH2), 4.95 (t, J ¼ 5.27 Hz, 1H, OH), 5.03 (t,
J ¼ 5.27 Hz, 1H, OH), 7.05 (dd, J68 ¼ 1.60 Hz, J56 ¼ 8.82 Hz, 1H, H-
6), 7.35 (d, J68 ¼ 1.37 Hz, 1H, H-8), 8.31 (d, J56 ¼ 8.93 Hz, 1H, H-5),
8.51 (d, J34¼ 6.41 Hz,1H, H-4), 8.63 (d, J34¼ 6.64 Hz,1H, H-3), 13C
NMR (DMSO- d6) d: 16.78, 22.73, 26.04, 39.52, 47.94, 56.30, 59.96,
60.33, 70.96, 95.33, 113.20, 113.72, 114.73, 124.85, 132.89, 135.12,
136.06, 139.94, 147.71, 163.15.
4.1.9. 7-(2-Hydroxyethoxy)-2,9-bis(2-hydroxyethyl)-1-methyl-b-
carbolin-2-ium bromide, 4h
The title compound was synthesized from 4d (0.242 g,
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H2 (1 bar) in 20 ml of ethanol. The reaction was followed by TLC
(85:15 dichloromethane: ethanol). After completion of the reaction,
the mixture was ﬁltered under celite and was evaporated under
vacuum. The crude extract was crystallized with hot ethanol to give
the title compound. A yellow solid was obtained after crystalliza-
tion in EtOH. Yield 82%, Mp 192e194 C, MS: [M]þ 331.0, Rf ¼ 0.1
(85:15 dichloromethane: ethanol), 1H NMR (DMSO- d6) d: 3.25 (s,
3H, CH3), 3.77e3.86 (m, 6H, CH2eOH þ CH2eOH þ CH2eOH), 4.19
(t, J ¼ 4.58 Hz, 2H, OeCH2), 4.75e4.80 (m, 4H, NeCH2 þ NeCH2),
4.95 (t, J ¼ 5.04 Hz, 1H, CH2eOH), 5.04 (bs, 1H, CH2eOH), 5.17 (bs,
1H, CH2eOH), 7.05 (dd, J68 ¼ 1.37 Hz, J56 ¼ 8.70 Hz, 1H, H-6), 7.53
(d, J68 ¼ 1.37 Hz, 1H, H-8), 8.31 (d, J56 ¼ 8.70 Hz, 1H, H-5),
8.48e8.53 (m, 2H, H-4, H-3), 13C NMR (DMSO- d6) d: 17.14, 47.95,
59.41, 59.96, 60.36, 60.69, 70.94, 95.35,113.19, 113.68, 114.11,124.83,
133.02, 135.83, 135.96, 140.59, 147.81, 163.16, Anal. Calcd for
C18H23BrN2O4: C, 52.56%; H, 5.64%; N, 6.81%. Found: C, 52.96%; H,
5.72%; N, 6.40%.
4.1.10. 7-(Isopentyloxy)-1-methyl-9-propyl-b-carboline, 5a
The title compound was synthesized according to the general
procedure C from 3 (1.265 g, 4.7 mmol) in the presence of iodo-
propane (1.198 g, 7.05 mmmol), sodium hydride (0.56 g,
23.5 mmol) in 180 ml of DMF. A red solid was obtained. Yield 83%,
Mp 82e83 C, MS: [MþH]þ 311.1, Rf ¼ 0.8 (85:15 dichloromethane:
ethanol), 1H NMR (DMSO-d6) d: 0.88 (t, J ¼ 7.33 Hz, 3H, CH2eCH3),
0.93 (d, J ¼ 6.64 Hz, 6H, CH-(CH3)2), 1.61e1.87 (m, 5H, CH2e CH-
(CH3)2 þ CH2eCH3), 2.89 (s, 3H, CH3), 4.11 (t, J ¼ 6.41 Hz, 2H,
OeCH2), 4.47 (t, J ¼ 7.33 Hz, 2H, NeCH2), 6.81 (dd, J56 ¼ 8.59 Hz,
J68 ¼ 1.60 Hz, 1H, H-6), 7.16 (d, J68 ¼ 1.60 Hz, 1H, H-8), 7.82 (d,
J34 ¼ 5.04 Hz, 1H, H-4), 8.02 (d, J56 ¼ 8.47 Hz, 1H, H-5), 8.12 (d,
J34 ¼ 5.04 Hz, 1H, H-3), 13C NMR (DMSO-d6) d: 11.47, 23.05, 23.13,
24.16, 38.10, 25.15, 45.88, 66.88, 94.91, 109.92, 112.72, 114.62,
122.85, 128.93, 135.14, 138.23, 140.99, 143.38, 160.43, Anal. Calcd for
C20H26N2O: C, 77.38%; H 8.44%; N, 9.02%. Found: C, 77.27%; H, 8.47%;
N, 8.81%.
4.1.11. 1-Methyl-7-Propoxy-9-propyl-b-carboline, 5b
The title compound was synthesized according to the general
procedure A from harmol (1.50 g, 4.78 mmol) in the presence of
bromopropane (0.8 ml, 9.55 mmol) and potassium hydroxide in
30 ml of DMF. A yellow solid was obtained. Yield: 52%, Mp:
73.1e75 C, MS: [MþH]þ 283.2, Rf ¼ 0.40 (95:5 dichloromethane:
ethanol), 1H NMR (DMSO- d6) d: 0.87 (t, J ¼ 7.33 Hz, 3H, CH2eCH3),
0.99 (t, J ¼ 7.33 Hz, 3H, CH2eCH3), 3.31 (s, 3H, CH3), 4.04 (t,
J¼ 6.64 Hz, 2H, OeCH2eCH2), 4.46 (t, J¼ 7.56 Hz, 2H, OeCH2eCH2),
6.82 (dd, J68¼ 2.06 Hz, J56¼ 8.70,1H, H-6), 7.15 (d, J68¼ 1.83 Hz,
1H, H-8), 7.83(d, J34 ¼ 5.04 Hz, 1H, H-4)), 8.03(d, J56 ¼ 8.47 Hz,
1H, H-5), 8.46 (d, J34 ¼ 5.04 Hz, 1H, H-3), 13C NMR (DMSO- d6) d:
11.07, 11.47, 22.67, 23.57, 24.13, 45.88, 69.93, 94.85, 109.90, 112.74,
122.86, 128.92, 135.13, 138.21, 140.99, 143.37, 160.44.
4.1.12. 2-Ethyl-1-methyl-7-propoxy-9-propyl-b-carbolin-2-ium
bromide, 5c
The title compound was synthesized according to the general
procedure D from 5b (0.309 g, 1.15 mmol) in the presence of bro-
moethane (0.8 ml, 10.5 mmol) in 10 ml of THF. A white solid was
obtained after crystallization in EtOH. Yield 75%, Mp 218 C, MS:
[M]þ 311.3, Rf ¼ 0.3 (85:15 dichloromethane: ethanol), 1H NMR
(CD3OD) d: 1.03 (t, J¼ 7.56 Hz, 3H, CH2eCH3), 1.10 (t, J¼ 7.33 Hz, 3H,
CH2eCH3), 1.62 (t, J ¼ 7.10, 3H, NeCH2eCH3), 1.85e2.00 (m, 4H,
NeCH2eCH2þOeCH2eCH2), 3.24 (s, 3H), 4.15 (t, J ¼ 6.64 Hz, 2H,
OeCH2), 4.64 (t, J ¼ 7.79, 2H, NeCH2), 4.75 (q, J ¼ 7.10, 2H, NeCH2),
7.05 (dd, J68 ¼ 2.06 Hz, J56 ¼ 8.93, 1H, H-6), 7.20 (d,
J68 ¼ 2.06 Hz, 1H, H-8), 8.93(d, J56 ¼ 8.93 Hz, 1H, H-5), 8.33(d,J34 ¼ 6.64 Hz, 1H, H-4), 8.46 (d, J34 ¼ 6.64 Hz, 1H, H-3), 13C NMR
(CD3OD) d: 9.56, 9.92, 14.84, 15.04, 22.27, 23.63, 46.80, 52.80, 70.13,
93.70, 112.90, 113.51, 114.09, 123.84, 133.69, 133.92, 135.09, 138.42,
147.99, 163.88, Anal. Calcd for C17H20BrN2O: C, 61.38%; H, 6.95%; N,
7.16%. Found: C, 61.07%; H, 7.19%; N,7.32%.
4.1.13. 2-Isopentyl-1-methyl-7-propoxy-9-propyl-b-carbolin-2-ium
bromide, 5d
The title compound was synthesized according to the general
procedure D from 5b (0.513 g, 1.8 mmol) in the presence of 1-
bromo-3-methylbutane (2.2 ml, 18.3 mmol) in 17 ml of THF. A
yellow solid was obtained after crystallization in EtOH. Yield 13%,
Mp 227e228 C, MS: [M]þ 353.4, Rf ¼ 0.3 (85:15 dichloromethane:
ethanol), 1H NMR (CD3OD) d: 1.00e1.16 (m, 12H, CH-
(CH3)2 þ CH2eCH3þCH2eCH3), 1.80e1.99 (m, 7H, CH2eCH-
(CH3)2þ CH2eCH3þ CH2eCH3), 3.23 (s, 3H, CH3), 4.15 (t, J¼ 6.41 Hz,
2H, OeCH2), 4.60e4.73 (m, 4H, NeCH2, NeCH2), 7.05 (dd,
J56 ¼ 8.70 Hz, J68 ¼ 2.06 Hz, 1H, H-6), 7.20 (d, J68 ¼ 2.06 Hz, 1H,
H-8), 8.21 (d, J56¼ 8.93 Hz, 1H, H-5), 8.33 (d, J34¼ 6.41 Hz, 1H, H-
4), 8.47 (d, J34 ¼ 6.64 Hz, 1H, H-3), 13C NMR (CD3OD) d: 9.56, 9.92,
21.33, 22.26, 23.60, 26.10, 39.35, 46.79, 56.18, 70.14, 93.70, 112.90,
113.53, 113.96, 123.85, 133.66, 134.32, 135.15, 138.26, 148.02, 163.91,
Anal. Calcd for C23H33BrN2O: C, 63.74%; H, 7.67%; N, 6.46%. Found: C,
64.09%; H, 7.85%; N, 6.66%.
4.1.14. 7-(Benzyloxy)-2-ethyl-1-methyl-9-propyl-b-carbolin-2-ium
bromide, 5e
The title compound was synthesized according to the general
procedure D from 2w (0.305 g, 0.9 mmol) in the presence of bro-
moethane (0.7 ml, 9 mmol) in 15 ml of THF. A yellow solid was
obtained. Yield 85%, Mp 217 C, MS: [M]þ 359.2, Rf ¼ 0.2 (85:15
dichloromethane: ethanol), 1H NMR (CD3OD) d: 0.99 (t, J ¼ 7.33 Hz,
3H, CH2eCH3), 1.61 (t, J ¼ 7.33 Hz, 3H, NeCH2eCH3), 1.84e1.93 (m,
2H, NeCH2eCH2), 3.23 (s, 3H, CH3), 4.62 (t, J ¼ 7.79 Hz, 2H,
NeCH2eCH2), 4.75 (q, J ¼ 7.33 Hz, 2H, NeCH2eCH3), 5.32 (s, 2H,
OeCH2), 7.14 (dd, J56¼ 8.70 Hz, J68 ¼ 2.06 Hz, 1H, H-6), 7.28e7.51
(m, 6H, AreH þ H-8), 8.23 (d, J56 ¼ 8.93 Hz, 1H, H-5), 8.35 (d,
J34 ¼ 6.64 Hz, 1H, H-4), 8.47 (d, J34 ¼ 6.64 Hz, 1H, H-3), 13C NMR
(CD3OD) d: 9.90, 14.99, 23.52, 29.34, 46.83, 52.81, 70.40, 94.55,
113.15, 113.81, 114.24, 123.93, 127.44, 127.89, 128.35, 133.64, 133.90,
135.19, 136.65, 138.46, 147.81, 163.26, Anal. Calcd for C24H27BrN2O:
C, 65.60%; H, 6.19%; N, 6.38%. Found: C, 65.94%; H, 6.35%; N, 6.27%.
4.1.15. 7-(Benzyloxy)-2-isopentyl-1-methyl-9-propyl-b-carbolin-2-
ium bromide, 5f
The title compound was synthesized according to the general
procedure D from 2w (0.399 g, 1.2 mmol) in the presence of 1-
bromo-3-methylbutane (2.2 ml, 18 mmol) in 15 ml of THF. A
white solid was obtained. Yield 45%, Mp 222e224 C, MS: [M]þ
401.3, Rf ¼ 0.4 (85:15 dichloromethane: ethanol), 1H NMR (CD3OD)
d: 0.99 (t, J ¼ 7.33 Hz, 3H, CH2eCH3), 1.07 (d, J ¼ 6.41 Hz, 6H, CH-
(CH3)2), 1.81e1.93 (m, 5H, CH2eCH3þ CH2e CH-(CH3)2), 3.22 (s, 3H,
CH3), 4.62 (t, J ¼ 7.56 Hz, 2H, NeCH2), 4.69 (t, J ¼ 7.79 Hz, 2H,
NeCH2), 5.32 (s, 2H, OeCH2), 7.14 (dd, J56¼ 8.93 Hz, J68¼ 2.06 Hz,
1H, H-6), 7.28e7.52 (m, 6H, AreH þ H-8), 8.23 (d, J56 ¼ 8.93 Hz,
1H, H-5), 8.34 (d, J34 ¼ 6.64 Hz, 1H, H-4), 8.46 (d, J34 ¼ 6.64 Hz,
1H, H-3), 13C NMR (CD3OD) d: 9.90, 14.97, 21.31, 23.54, 26.10, 39.32,
46.85, 56.20, 70.40, 94.56, 113.15, 113.82, 114.07, 123.92, 127.43,
127.88, 128.35, 133.62, 134.32, 135.19, 136.65, 138.52, 147.82, 163.27,
Anal. Calcd for C27H33BrN2O: C, 67.35%; H, 6.91%; N, 5.82%. Found: C,
67.10%; H, 6.77%; N, 5.93%.
4.1.16. 7-(Benzyloxy)-2-isobutyl-1-methyl-9-propyl-b-carbolin-2-
ium bromide, 5g
The title compound was synthesized according to the general
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bromo-3-methylpropane (2.0 ml, 18 mmol) in 15 ml of THF. A yel-
low solid was obtained. Yield 8%, Mp 237 C, MS: [M]þ 387.3,
Rf¼ 0.4 (85:15 dichloromethane: ethanol), 1H NMR (CD3OD) d: 0.99
(t, J ¼ 7.56 Hz, 3H, CH2eCH3), 1.03 (d, J ¼ 6.64 Hz, 6H, CH-(CH3)2),
1.83e1.93 (m, 2H, CH2eCH3),2.25e2.36 (m, 1H, CH-(CH3)2), 3.23 (s,
3H, CH3),4.55 (d, J ¼ 7.56 Hz, 2H, NeCH2), 4.63 (t, J ¼ 7.56 Hz, 2H,
NeCH2), 5.32 (s, 2H, OeCH2), 7.15 (dd, J56 ¼ 8.82 Hz,
J68 ¼ 2.06 Hz, 1H, H-6), 7.28e7.52 (m, 6H, AreH þ H-8), 8.25 (d,
J56 ¼ 8.93 Hz, 1H, H-5), 8.34 (d, J34 ¼ 6.64 Hz, 1H, H-4), 8.42 (d,
J34 ¼ 6.64 Hz, 1H, H-3), 13C NMR (CD3OD) d: 9.89, 15.21, 18.35,
23.57, 29.54, 46.87, 63.95, 70.41, 94.58, 113.17, 113.50, 113.87, 123.99,
127.44, 127.89, 128.35, 133.69, 135.12, 135.35, 136.64, 138.83, 147.91,
163.35, Anal. Calcd for C26H31BrN2O: C, 66.81%; H, 6.68%; N, 5.99%.
Found: C, 66.61%; H, 6.81%; N, 5.75%.
4.1.17. 2-ethyl-7-(isopentyloxy)-1-methyl-9-propyl-b-carbolin-2-
ium bromide, 5h
The title compound was synthesized according to the general
procedure D from 5a (0.309 g, 0.99 mmol) in the presence of bro-
moethane (0.8 ml, 10.7 mmol) in 15 ml of THF. A yellow solid was
obtained after crystallization in EtOH. Yield 42%, Mp 215 C, MS:
[M]þ 339.3, Rf ¼ 0.2 (85:15 dichloromethane: ethanol), 1H NMR
(CD3OD) d: 0.98e1.08 (m, 9H, CH-(CH3)2 þ CH2eCH3), 1.61 (t,
J ¼ 7.33 Hz, 3H, NeCH2eCH3), 1.76 (m, 2H, OeCH2eCH2), 1.85e1.97
(m, 3H, CH2eCH3þ CH-(CH3)2), 3.24 (s, 3H, CH3), 4.23 (t, J¼ 6.41 Hz,
2H, OeCH2), 4.66 (t, J ¼ 7.79 Hz, 2H, NeCH2), 4.75 (q, J ¼ 7.33 Hz,
2H, NeCH2), 7.06 (dd, J56 ¼ 8.70 Hz, J68 ¼ 2.06 Hz, 1H, H-6), 7.22
(d, J68¼ 1.83 Hz, 1H, H-8), 8.22 (d, J56¼ 8.70 Hz,1H, H-5), 8.34 (d,
J34 ¼ 6.64 Hz, 1H, H-4), 8.46 (d, J34 ¼ 6.64 Hz, 1H, H-3), 13C NMR
(CD3OD) d: 9.92,14.81,15.02, 21.63, 23.63, 24.96, 37.73, 46.80, 52.79,
67.03, 93.71, 112.92, 113.54, 114.09, 123.84, 133.71, 133.90, 135.10,
138.42, 148.03, 163.86, Anal. Calcd for C22H31BrN2O: C, 63.00%; H,
7.45%; N, 6.68%. Found: C, 62.85%; H, 7.38%; N, 6.71%.
4.1.18. 7-(Isopentyloxy)-1-methyl-2,9-dipropyl-b-carbolin-2-ium
bromide, 5i
The title compound was synthesized according to the general
procedure D from 5a (0.311 g, 1.00 mmol) in the presence of bro-
mopropane (0.9 ml, 10.0 mmol) in 15 ml of THF. A yellow solid was
obtained after crystallization in EtOH. Yield 29%, Mp 206e208 C,
MS: [M]þ 353.3, Rf ¼ 0.2 (85:15 dichloromethane: ethanol), 1H
NMR (CD3OD) d: 1.00e1.10 (m, 12H, CH-
(CH3)2 þ CH2eCH3 þ CH2eCH3), 1.73e1.78 (m, 2H, OeCH2eCH2),
1.83e2.06 (m, 5H, CH2eCH3þ CH2eCH3þ CH-(CH3)2), 3.23 (s, 3H,
CH3), 4.23 (t, J ¼ 6.64 Hz, 2H, OeCH2), 4.66 (t, J ¼ 7.79 Hz, 4H,
NeCH2þ NeCH2), 7.06 (dd, J56¼ 8.93 Hz, J68¼ 2.06 Hz, 1H, H-6),
7.22 (d, J68 ¼ 2.06 Hz, 1H, H-8), 8.22 (d, J56 ¼ 8.93 Hz, 1H, H-5),
8.33 (d, J34¼ 6.64 Hz,1H, H-4), 8.46 (d, J34¼ 6.64 Hz,1H, H-3), 13C
NMR (CD3OD) d: 9.66, 9.92, 14.96, 21.64, 23.64, 23.90, 24.96, 37.73,
46.81, 58.76, 67.05, 93.73, 112.92, 113.55, 113.76, 123.87, 133.71,
134.47, 135.14, 138.50, 148.05, 163.88, Anal. Calcd for C23H33BrN2O:
C, 63.74%; H, 7.67%; N, 6.46%. Found: C, 63.37%; H, 7.74%; N, 6.65%.
4.1.19. 2-Isopentyl-7-(isopentyloxy)-1-methyl-9-propyl-b-carbolin-
2-ium bromide, 5j
The title compound was synthesized according to the general
procedure D from 5a (0.499 g, 1.6 mmol) in the presence of 1-
bromo-3-methylpropane (2.0 ml, 16 mmol) in 17 ml of THF. A yel-
low solid was obtained after crystallization in EtOH. Yield 18%, Mp
220e222 C, MS: [M]þ 381.4, Rf ¼ 0.3 (85:15 dichloromethane:
ethanol), 1H NMR (CD3OD) d: 0.99e1.08 (m, 15H, CH-
(CH3)2 þ CH2eCH3 þ CH-(CH3)2), 1.73e1.79 (m, 2H, OeCH2eCH2),
1.84e1.99 (m, 6H, CH-(CH3)2 þ CH-
(CH3)2 þ NeCH2eCH2 þ NeCH2eCH2), 3.23 (s, 3H, CH3), 4.23 (t,J ¼ 6.41 Hz, 2H, OeCH2), 4.64e4.72 (m, 4H, NeCH2 þ NeCH2), 7.06
(dd, J56 ¼ 8.70 Hz, J68 ¼ 2.06 Hz, 1H, H-6), 7.22 (d, J68 ¼ 2.06 Hz,
1H, H-8), 8.22 (d, J56 ¼ 8.93 Hz, 1H, H-5), 8.33 (d, J34 ¼ 6.41 Hz,
1H, H-4), 8.46 (d, J34 ¼ 6.41 Hz, 1H, H-3), 13C NMR (CD3OD) d: 9.91,
14.96, 21.32, 21.63, 23.62, 24.96, 26.11, 37.73, 39.34, 46.79, 56.16,
67.04, 93.72, 112.92, 113.56, 113.94, 123.85, 133.70, 134.31, 135.15,
138.36, 148.05, 163.90, Anal. Calcd for C25H37BrN2O: C, 65.07%; H,
8.08%; N, 6.07%. Found: C, 65.12%; H, 8.23%; N, 6.18%.
4.2. CoMFA
4.2.1. Data set
In vitro antiproliferative activity against Hs683 glioma cells was
chosen to construct a 3D-QSAR model on 49 b-carbolines com-
pounds (1, 2aeas and 4feh compounds). The IC50 (M) obtained on
this cell line was transformed into pIC50 (-logIC50). Data set was
divided randomly into a training set (80%: 39 compounds) and a
test set (20%: 10 compounds) using Discovery Studio 3.5.
4.2.2. Alignment
Alignment was generated using LigandScout 3.03 software. This
alignment was elaborated in two steps: ﬁrst step was to generate a
pharmacophore using 2a, 2ad and 2ap as training set, usingmerged
features. Based on this pharmacophore, features from b-carboline
tricycle and positive charge were removed in order to give a bias
pharmacophore. Based on this bias pharmacophore, the second
step was to generate a second pharmacophore using 2c, 2ac, 2an
and 2aq as training set. This combination of steps induces the best
alignment for the whole b-carboline discussed in this work.
4.2.3. CoMFA analyse
CoMFA model was generated using Sybyl 8.1 software (TRIPOS
Associates Inc.). Charges were calculated by the MMFF94s method
in the software. CoMFA calculations were performed using default
values. Steric and electrostatics ﬁelds were calculated at each grid
points using an sp3 carbon atom probe with 1.52 Å Van der Waals
radius for steric ﬁeld and a þ1.0 charge for electrostatic ﬁled, with
an energy cut-off value of 30 kcal/mol.
4.2.4. Partial Least Square (PLS) analyses
In order to evaluate statistically the 3D-QSAR model, PLS
regression was used. A Leave-One-Out method was performed in
order to obtain a crossvalidated coefﬁcient correlation and the
optimal number of components used in the ﬁnal analysis. A column
ﬁltering of 2.0 kcal/mol was set. The non-crossvalidation analysis
was performed and leads to a conventional correlation coefﬁcient,
the standard error of estimate and the Fisher-test value which
determine the goodness-of-ﬁt.
4.3. In vitro growth inhibitory activity
MTT colorimetric assay was performed on different cancerous
cells (U373, T98G, Hs683, SKMEL-28, A549, MCF-7) using a protocol
described previously [15]. The histological types and origins of the
six cancer cell lines that were used for the MTT colorimetric assay
are as follows. The cell lines were obtained from the American Type
Culture Collection (ATCC, Manassas, VA), the European Collection of
Cell Culture (ECACC, Salisbury, UK) and the Deutsche Sammlung
von Mikroorganismen und Zellkulturen (DSMZ, Braunschweig,
Germany). The analysed cell lines include the U373 (ECACC code
08061901), Hs683 (ATCC code HTB-138) and T98G (ATCC code CRL-
1690) gliomas; the SKMEL-28 melanoma (ATCC code HTB-72); the
MCF-7 breast (DSMZ code ACC115) and the A549 non-small-cell
lung (NSCLC; DSMZ code ACC107) carcinoma models. All cell lines
are from human origin.
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Quantitative videomicroscopy was performed on U373, Hs683
and SKMEL28 cancer cells at the IC50 determined by the MTT
colorimetric test for each compound of interest, using the same
protocol as previously [5].
4.5. Solubility
Solubility experiment was performed using a protocol described
previously [23].
4.6. ADME prediction
Human intestinal absorption and blood brain barrier penetra-
tion after oral administration were calculated using Discovery
Studio 3.5 software [18]. For human intestinal absorption, a model
was developed using 182 compounds in the training set with de-
scriptors such as AlogP98 and 2D polar surface area [20]. Well
absorbed compounds (>90% absorbed) are situated in an ellipse of
95% and 99% of conﬁdence. Blood brain barrier model was gener-
ated using 102 compounds in a training set and 86 compounds in a
test set. This model was after validated twice using 881 compounds
known as CNS compounds from the CMC database and using 124
compounds with known logBB value [18]. Prediction of BBB pene-
tration is divided into 4 levels (very high to low) included onto 95%
and 99% conﬁdence ellipse and an undeﬁned level excluded from
the conﬁdence ellipses.
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